Based on these characteristics, HCN2 is considered a potential pharmacological target for the development of novel analgesics that are effective against neuropathic pain and migraine (Bernard Healey et al., 2021; Tsantoulas et al., 2016; Tsantoulas et al., 2022). This evidence concerns the gene HCN2 and migraine disorder.